Business Wire

BLUEHOLE-NEW

28.4.2022 04:33:09 CEST | Business Wire | Press release

Share
Bluehole Publishes an Industry Comment on the First FDA-authorized Closed Pod Vape Equipped with FEELM Tech.

China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on the first FDA-authorized closed pod vape equipped with FEELM Tech.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427006228/en/

Here below is the full article:

The FDA (the Food and Drug Administration) has issued marketing granted orders to NJOY Ace and its tobacco-flavored e-liquid pods on April 26. It is the first e-cigarette authorized by the FDA that is equipped with ceramic coils and manufactured by FEELM, the flagship atomization tech brand belonging to SMOORE.

NJOY has partnered with SMOORE since 2009. NJOY Ace was launched in 2018 and is powered by FEELM inside, the world’s first black ceramic atomization coil with metallic film. As the first ceramic coil e-cigarette and pod vape authorized by the FDA, NJOY Ace's approval for sale fully showcases the harm reduction potential of FEELM ceramic coil. According to the FDA, NJOY Ace is authorized for sale because "chemical testing was sufficient to determine that overall harmful and potentially harmful constituent (HPHC) levels in the aerosol of these products is lower than in combusted cigarette smoke."

Based on PMTA requirements, SMOORE has established a comprehensive analytical testing and safety assessment system, including the vaping industry's first corporate toxicology laboratory, which explores the health impacts of exposure to e-cigarette vapor by means of cytotoxicity test, evaluating the reaction of living cells to different components of e-cigarette vapor. The company has also developed the third generation of in-house safety standards SMOORE 3.0, which covers all of the PMTA tests and HPHCs (Harmful and Potentially Harmful Constituents) listed by the FDA.

“The principle of PMTA is to scientifically and systematically substantiate harm reduction performance of the vaping product and show it is appropriate for the protection of the public health (APPH)”, said Dr. Long, Director of SMOORE Analytical Testing and Safety Assessment Center. "The manufacturer must demonstrate the product's potential to switch adult smokers while preventing youth and non-smokers from nicotine addiction," which could explain that all the FDA-authorized vaping products are tobacco-flavored, and popular flavored products have been issued Marketing Denial Orders. It also indicates that vaping manufacturers shall focus on tobacco flavor reproduction and improve harm reduction performance, in order to be approved under the PMTA pathway.

According to Nielsen, for the two weeks ended April 9, 2022, Vuse has surpassed Juul and become the No.1 in the U.S e-cigarette sales, with a market share of 35%. Its flagship product Vuse Alto is also equipped with FEELM ceramic coils. As the No.3 player in the U.S, NJOY accounts for approximately 3.1% market share. Moreover, a federal judge has required the FDA to provide progress reports on PMTAs submitted by major vaping brands. It is expected that more major vaping brands, such as Vuse and Juul, will receive their FDA status reports soon.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/49641

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release

First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by

Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release

Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi

KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release

- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC

SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 14:06:00 CEST | Press release

Integrated execution model combines multiple disciplines to improve recovery from mature offshore assets Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase reco

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 12:00:00 CEST | Press release

Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye